ruxolitinib + panobinostat
ApprovedActive 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Primary Myelofibrosis
Conditions
Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia, Thalassemia
Trial Timeline
Mar 5, 2015 → Sep 16, 2027
NCT ID
NCT02386800About ruxolitinib + panobinostat
ruxolitinib + panobinostat is a approved stage product being developed by Novartis for Primary Myelofibrosis. The current trial status is active. This product is registered under clinical trial identifier NCT02386800. Target conditions include Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease.
What happened to similar drugs?
20 of 20 similar drugs in Primary Myelofibrosis were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
20
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02386800 | Approved | Active |
Competing Products
20 competing products in Primary Myelofibrosis